BrightHeart will officially introduce the platform to European clinicians during the Fetal Medicine Foundation (FMF) World Congress in Vienna, taking place from June 28 to July 2, 2026.
If approved, MAVIRET would become one of the few therapies in the European Union indicated for both acute and chronic HCV infection.
The financing consortium includes Proparco, the European Investment Bank through the Human Development Accelerator initiative, and the International Finance Corporation.
The partnership aligns with Africa CDC’s Health Security and Sovereignty Agenda, which seeks to help African countries build stronger systems that can prevent, detect, and respond to disease threats while reducing reliance on external support.